These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 26718210)

  • 1. Fusobacterium nucleatum, inflammation, and immunity: the fire within human gut.
    Bashir A; Miskeen AY; Hazari YM; Asrafuzzaman S; Fazili KM
    Tumour Biol; 2016 Mar; 37(3):2805-10. PubMed ID: 26718210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer.
    Nosho K; Sukawa Y; Adachi Y; Ito M; Mitsuhashi K; Kurihara H; Kanno S; Yamamoto I; Ishigami K; Igarashi H; Maruyama R; Imai K; Yamamoto H; Shinomura Y
    World J Gastroenterol; 2016 Jan; 22(2):557-66. PubMed ID: 26811607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fusobacterium nucleatum and T Cells in Colorectal Carcinoma.
    Mima K; Sukawa Y; Nishihara R; Qian ZR; Yamauchi M; Inamura K; Kim SA; Masuda A; Nowak JA; Nosho K; Kostic AD; Giannakis M; Watanabe H; Bullman S; Milner DA; Harris CC; Giovannucci E; Garraway LA; Freeman GJ; Dranoff G; Chan AT; Garrett WS; Huttenhower C; Fuchs CS; Ogino S
    JAMA Oncol; 2015 Aug; 1(5):653-61. PubMed ID: 26181352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fusobacterium nucleatum: an emerging bug in colorectal tumorigenesis.
    Bashir A; Miskeen AY; Bhat A; Fazili KM; Ganai BA
    Eur J Cancer Prev; 2015 Sep; 24(5):373-85. PubMed ID: 25569450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fusobacterium nucleatum and colorectal cancer: A mechanistic overview.
    Hashemi Goradel N; Heidarzadeh S; Jahangiri S; Farhood B; Mortezaee K; Khanlarkhani N; Negahdari B
    J Cell Physiol; 2019 Mar; 234(3):2337-2344. PubMed ID: 30191984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment.
    Yu YN; Yu TC; Zhao HJ; Sun TT; Chen HM; Chen HY; An HF; Weng YR; Yu J; Li M; Qin WX; Ma X; Shen N; Hong J; Fang JY
    Oncotarget; 2015 Oct; 6(31):32013-26. PubMed ID: 26397137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diets That Promote Colon Inflammation Associate With Risk of Colorectal Carcinomas That Contain Fusobacterium nucleatum.
    Liu L; Tabung FK; Zhang X; Nowak JA; Qian ZR; Hamada T; Nevo D; Bullman S; Mima K; Kosumi K; da Silva A; Song M; Cao Y; Twombly TS; Shi Y; Liu H; Gu M; Koh H; Li W; Du C; Chen Y; Li C; Li W; Mehta RS; Wu K; Wang M; Kostic AD; Giannakis M; Garrett WS; Hutthenhower C; Chan AT; Fuchs CS; Nishihara R; Ogino S; Giovannucci EL
    Clin Gastroenterol Hepatol; 2018 Oct; 16(10):1622-1631.e3. PubMed ID: 29702299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment.
    Kostic AD; Chun E; Robertson L; Glickman JN; Gallini CA; Michaud M; Clancy TE; Chung DC; Lochhead P; Hold GL; El-Omar EM; Brenner D; Fuchs CS; Meyerson M; Garrett WS
    Cell Host Microbe; 2013 Aug; 14(2):207-15. PubMed ID: 23954159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host.
    Strauss J; Kaplan GG; Beck PL; Rioux K; Panaccione R; Devinney R; Lynch T; Allen-Vercoe E
    Inflamm Bowel Dis; 2011 Sep; 17(9):1971-8. PubMed ID: 21830275
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Ye X; Wang R; Bhattacharya R; Boulbes DR; Fan F; Xia L; Adoni H; Ajami NJ; Wong MC; Smith DP; Petrosino JF; Venable S; Qiao W; Baladandayuthapani V; Maru D; Ellis LM
    Cancer Prev Res (Phila); 2017 Jul; 10(7):398-409. PubMed ID: 28483840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Analysis of Colon Cancer-Derived Fusobacterium nucleatum Subspecies: Inflammation and Colon Tumorigenesis in Murine Models.
    Queen J; Domingue JC; White JR; Stevens C; Udayasuryan B; Nguyen TTD; Wu S; Ding H; Fan H; McMann M; Corona A; Larman TC; Verbridge SS; Housseau F; Slade DJ; Drewes JL; Sears CL
    mBio; 2021 Feb; 13(1):e0299121. PubMed ID: 35130731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of
    Borowsky J; Haruki K; Lau MC; Dias Costa A; Väyrynen JP; Ugai T; Arima K; da Silva A; Felt KD; Zhao M; Gurjao C; Twombly TS; Fujiyoshi K; Väyrynen SA; Hamada T; Mima K; Bullman S; Harrison TA; Phipps AI; Peters U; Ng K; Meyerhardt JA; Song M; Giovannucci EL; Wu K; Zhang X; Freeman GJ; Huttenhower C; Garrett WS; Chan AT; Leggett BA; Whitehall VLJ; Walker N; Brown I; Bettington M; Nishihara R; Fuchs CS; Lennerz JK; Giannakis M; Nowak JA; Ogino S
    Clin Cancer Res; 2021 May; 27(10):2816-2826. PubMed ID: 33632927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between Fusobacterium nucleatum and antitumor immunity in colorectal cancer liver metastasis.
    Sakamoto Y; Mima K; Ishimoto T; Ogata Y; Imai K; Miyamoto Y; Akiyama T; Daitoku N; Hiyoshi Y; Iwatsuki M; Baba Y; Iwagami S; Yamashita YI; Yoshida N; Komohara Y; Ogino S; Baba H
    Cancer Sci; 2021 Nov; 112(11):4470-4477. PubMed ID: 34464993
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Hamada T; Zhang X; Mima K; Bullman S; Sukawa Y; Nowak JA; Kosumi K; Masugi Y; Twombly TS; Cao Y; Song M; Liu L; da Silva A; Shi Y; Gu M; Li W; Koh H; Nosho K; Inamura K; Keum N; Wu K; Meyerhardt JA; Kostic AD; Huttenhower C; Garrett WS; Meyerson M; Giovannucci EL; Chan AT; Fuchs CS; Nishihara R; Giannakis M; Ogino S
    Cancer Immunol Res; 2018 Nov; 6(11):1327-1336. PubMed ID: 30228205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
    Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
    IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perturbed human sub-networks by Fusobacterium nucleatum candidate virulence proteins.
    Zanzoni A; Spinelli L; Braham S; Brun C
    Microbiome; 2017 Aug; 5(1):89. PubMed ID: 28793925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TOX expression decreases with progression of colorectal cancers and is associated with CD4 T-cell density and Fusobacterium nucleatum infection.
    Chen T; Li Q; Zhang X; Long R; Wu Y; Wu J; Fu X
    Hum Pathol; 2018 Sep; 79():93-101. PubMed ID: 29792893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Fusobacterium nucleatum infection and colorectal cancer: A Mexican study.
    Cuellar-Gómez H; Ocharán-Hernández ME; Calzada-Mendoza CC; Comoto-Santacruz DA
    Rev Gastroenterol Mex (Engl Ed); 2022; 87(3):277-284. PubMed ID: 34312118
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Yin H; Miao Z; Wang L; Su B; Liu C; Jin Y; Wu B; Han H; Yuan X
    Aging (Albany NY); 2022 Feb; 14(4):1941-1958. PubMed ID: 35212644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Significance of
    Zhang N; Liu Y; Yang H; Liang M; Wang X; Wang M; Kong J; Yuan X; Zhou F
    Pathol Oncol Res; 2021; 27():1609846. PubMed ID: 34305476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.